NEPH

Business Context and Reporting Period

Company: Nephros, Inc. (NEPH)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: Nephros develops and markets high-performance water filtration solutions for medical (infection control, dialysis) and commercial markets. The company operates as a single segment and is classified as a smaller reporting company.

Key Financial Metrics

Cash Flow: Net cash provided by operating activities was $0.32 million for Q1 2025, compared to a use of $0.67 million in Q1 2024. The improvement was driven by net income and a decrease in inventory, partially offset by an increase in accounts receivable.

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 38% year-over-year, driven by strong programmatic reorders, new active sites, and emergency response sales related to waterborne pathogen regulations. A price increase implemented in February 2025 also contributed.
• Profitability Turnaround: The company reported a net income of $0.56 million, reversing a net loss of $0.17 million in the prior year period. Operating income improved by $0.77 million.
• Margin Expansion: Gross margin percentage increased from 62% to 65%, attributed to a favorable product mix, the price increase, and lower inventory write-offs.
• Expense Management: Selling, general, and administrative (SG&A) expenses rose 5% due to higher commissions and stock compensation, though this was partially offset by the absence of a one-time stock compensation reversal recorded in Q1 2024.

Outlook, Risks, and Contingencies

Management Commentary & Liquidity: Management believes current cash balances are sufficient to fund operations for at least the next 12 months. However, the company notes that elevated emergency response sales may not persist throughout the year following the change in U.S. presidential administration. The company maintains a focus on expense management to sustain profitability.

Material Weakness in Internal Controls: The company identified a material weakness in internal controls over financial reporting regarding the recognition of revenue from contracts with multiple performance obligations (products and services) under ASC 606. While no material misstatement occurred in the current period, management is working with consultants to remediate this issue.

Risk Factors:

• Tariffs and Supply Chain: The company relies on an exclusive supplier in the European Union (Medica S.p.A.) for filtration materials. New or increased U.S. tariffs could materially increase costs and affect margins.
• Customer Concentration: Two customers accounted for 30% of revenue in Q1 2025 (down from 38% in Q1 2024).
• Contractual Obligations: The company has minimum annual purchase commitments with Medica through 2028. Failure to meet these could result in a breach of contract.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of "emergency response" sales and the impact of the recent change in U.S. administration on future demand.
• Internal Controls: Monitor the remediation plan for the material weakness in revenue recognition controls to ensure future financial reporting accuracy.
• Supply Chain Exposure: Assess the potential financial impact of U.S. tariffs on imports from the EU, given the reliance on a single supplier for critical filtration materials.
• Contractual Compliance: Confirm the company's ability to meet minimum purchase commitments under the License and Supply Agreement with Medica for 2025 and beyond.
• Cash Burn vs. Generation: Track operating cash flow trends to ensure the company can maintain positive cash flow without needing to reduce headcount or R&D spending.